Changes of serum angiopoietin-like protein 2 and 4 levels and their relationship with ovarian interstitial hemodynamics in patients with PCOS

doi:10.11958/20222119

Abstract

Abstract:

Objective To investigate changes of serum Angptl2 and Angptl4 levels in patients with polycystic ovary syndrome (PCOS) and their relationship with ovarian interstitial hemodynamics. Methods A total of 123 PCOS patients (the PCOS group) and 41 healthy volunteers (the control group) were selected. The serum Angptl2 and Angptl4 levels, the peak systolic velocity (PSV), pulsation index (PI) and resistance index (RI) of ovarian interstitial were compared between the two groups. The relationship between Angptl2, Angptl4, PSV, PI, RI and PCOS and their predictive value to PCOS were analyzed. Results The PI and RI values of left and right ovarian interstitial were lower in the PCOS group than those in the control group, and PSV values were higher than those in the control group (P<0.05). Pearson analysis showed that serum Angptl2 and Angptl4 were positively correlated with PSV of left and right ovarian interstitial, and negatively correlated with PI and RI of left and right ovarian interstitial in patients with PCOS (P<0.01). Logistic regression results showed that high HOMA-IR (OR=1.921, 95%CI: 1.017-4.154), high BMI (OR=1.459, 95%CI: 1.085-3.220), high Angptl2 (OR=2.625, 95%CI: 1.330-6.324), high Angptl4 (OR=3.543, 95%CI: 1.915-8.147) levels were related factors affecting the occurrence of PCOS (P<0.05). Receiver operating characteristic curve (ROC) showed that the AUC (95%CI) of predicted PCOS were 0.747 (0.661-0.821) and 0.769 (0.685-0.841) when serum Angptl2 and Angptl4 were used alone. It was lower than that of 0.879 (0.793-0.921, P<0.05) for the combined application. Conclusion The abnormal levels of serum Angptl2 and Angptl4 in PCOS patients are related to the hemodynamics of ovarian interstitial, and they are closely related to the occurrence of PCOS, which can be used as reference indexes for the evaluation of PCOS.

Key words: polycystic ovary syndrome, ovarian interstitial, hemodynamics, angiopoietin-like protein 2, angiopoietin-like protein 4

CLC Number:

R711.75

Figures/Tables 8

References 24

[1]	乔杰, 李蓉, 李莉, 等. 多囊卵巢综合征流行病学研究[J]. 中国实用妇科与产科杂志, 2013, 29(11):849-852.
	QIAO J, LI R, LI L, et al. Epidemiology of polycystic ovary syndrome[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2013, 29(11):849-852.
[2]	WEI L, WU F, ZHANG J, et al. Evaluation of endocrine and metabolic changes in polycystic ovary syndrome by ultrasonic imaging features under an intelligent algorithm[J]. Comput Math Methods Med, 2022, 2022:1411943. doi:10.1155/2022/1411943.
[3]	魏鏡讚, 赵彦艳. 多囊卵巢综合征的卵巢血管生成[J]. 中国实用妇科与产科杂志, 2020, 36(6):567-570.
	WEI J Z, ZHAO Y Y. Ovarian angiogenesis in polycystic ovarian syndrome[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2020, 36(6):567-570. doi:10.19538/j.fk2020060121.
[4]	DAMBALA K, PASCHOU S A, MICHOPOULOS A, et al. Biomarkers of endothelial dysfunction in women with polycystic ovary syndrome[J]. Angiology, 2019, 70(9):797-801. doi:10.1177/0003319719840091.
[5]	LIU Y Z, ZHANG C, JIANG J F, et al. Angiopoietin-like proteins in atherosclerosis[J]. Clin Chim Acta, 2021, 521:19-24. doi:10.1016/j.cca.2021.06.024.
[6]	PARK J, CHOI Y, MIZUSHIMA R, et al. Dietary modification reduces serum angiopoietin-like protein 2 levels and arterial stiffness in overweight and obese men[J]. J Exerc Nutrition Biochem, 2019, 23(3):39-44. doi:10.20463/jenb.2019.0021.
[7]	JIANG Q, PAN Y, LI P, et al. ANGPTL4 expression in ovarian granulosa cells is associated with polycystic ovary syndrome[J]. Front Endocrinol(Lausanne), 2021, 12:799833. doi:10.3389/fendo.2021.799833.
[8]	GEISTHÖVEL F. A comment on the European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine consensus of the polycystic ovarian syndrome[J]. Reprod Biomed Online, 2003, 7(6):602-605. doi:10.1016/s1472-6483(10)62081-0.
[9]	WITCHEL S F, TEEDE H J, PEÑA A S. Curtailing PCOS[J]. Pediatr Res, 2020, 87(2):353-361. doi:10.1038/s41390-019-0615-1.
[10]	CHEN W, PANG Y. Metabolic syndrome and PCOS:pathogenesis and the role of metabolites[J]. Metabolites, 2021, 11(12):869. doi:10.3390/metabo11120869.
[11]	CELIK Ö, YILMAZ E, CELIK N, et al. Salusins,newly identified regulators of hemodynamics and mitogenesis,increase in polycystic ovarian syndrome[J]. Gynecol Endocrinol, 2013, 29(1):83-86. doi:10.3109/09513590.2012.706667.
[12]	DWIVEDI A, GANESH V, SHUKLA R C, et al. Colour Doppler evaluation of uterine and ovarian blood flow in patients of polycystic ovarian disease and post-treatment changes[J]. Clin Radiol, 2020, 75(10):772-779. doi:10.1016/j.crad.2020.05.023.
[13]	宋小青, 蔡迁, 王革玲, 等. 多囊卵巢综合征患者血清FGF-21、MCP-1、AngⅡ表达与胰岛素抵抗的关系[J]. 中国医师杂志, 2022, 24(5):790-792.
	SONG X Q, CAI Q, WANG G L, et al. Relationship between expression of FGF-21,MCP-1,AngⅡ and insulin resistance in patients with polycystic ovary syndrome[J]. Journal of Chinese Physician, 2022, 24(5):790-792. doi:10.3760/cma.j.cn431274-20210416-00441.
[14]	YANG L, LI T, ZHA L. Foxc2 alleviates ox-ldl-induced lipid accumulation,inflammation,and apoptosis of macrophage via regulating the expression of angptl2[J]. Inflammation, 2020, 43(4):1397-1410. doi:10.1007/s10753-020-01217-w.
[15]	HE Y, YANG W, GAN L, et al. Silencing HIF-1α aggravates non-alcoholic fatty liver disease in vitro through inhibiting PPAR-α/ANGPTL4 singling pathway[J]. Gastroenterol Hepatol, 2021, 44(5):355-365. doi:10.1016/j.gastrohep.2020.09.014.
[16]	FERNÁNDEZ-HERNANDO C, SUÁREZ Y. ANGPTL4:a multifunctional protein involved in metabolism and vascular homeostasis[J]. Curr Opin Hematol, 2020, 27(3):206-213. doi:10.1097/MOH.0000000000000580.
[17]	ZHOU Y, XIA M, CUI C, et al. Circulating exosomal mir-221 from maternal obesity inhibits angiogenesis via targeting angptl2[J]. Int J Mol Sci, 2021, 22(19):10343. doi:10.3390/ijms221910343.
[18]	LI M, HU J, YAO L, et al. Decreased ANGPTL4 impairs endometrial angiogenesis during peri-implantation period in patients with recurrent implantation failure[J]. J Cell Mol Med, 2020, 24(18):10730-10743. doi:10.1111/jcmm.15696.
[19]	陈奕男, 秦将均. 超声监测PCOS患者卵巢间质血流动力学变化及其与血清ES、VEGF的相关性分析[J]. 中国超声医学杂志, 2021, 37(4):453-456.
	CHEN Y N, QIN J J. Ultrasound monitoring of ovarian stromal hemodynamic changes and its correlation with serum Es and VEGF in patients with PCOS[J]. Chinese Journal of Ultrasound in Medicine, 2021, 37(4):453-456.
[20]	WEI J, ZHAO Y. MiR-185-5p Protects against angiogenesis in polycystic ovary syndrome by targeting VEGFA[J]. Front Pharmacol, 2020, 11:1030. doi:10.3389/fphar.2020.01030.
[21]	WEI Y, LU S, HU Y, et al. MicroRNA-135a regulates VEGFC expression and promotes luteinized granulosa cell apoptosis in polycystic ovary syndrome[J]. Reprod Sci, 2020, 27(7):1436-1442. doi:10.1007/s43032-020-00155-0.
[22]	WANG D, GUO Y, CHAI S, et al. Expression of angiopoietin-like protein 2 in ovarian tissue of rat polycystic ovarian syndrome model and its correlation study[J]. Reprod Biol Endocrinol, 2020, 18(1):94. doi:10.1186/s12958-020-00651-7.
[23]	SPITLER K M, SHETTY S K, CUSHING E M, et al. Chronic high-fat feeding and prolonged fasting in liver-specific ANGPTL4 knockout mice[J]. Am J Physiol Endocrinol Metab, 2021, 321(4):E464-E478. doi:10.1152/ajpendo.00144.2021.
[24]	SCHINZARI F, VIZIOLI G, CAMPIA U, et al. Variable changes of circulating ANGPTL3 and ANGPTL4 in different obese phenotypes:relationship with vasodilator dysfunction[J]. Biomedicines, 2021, 9(8):1037. doi:10.3390/biomedicines9081037.

组别		n	年龄/岁		BMI/（kg/m²）		FSH/（U/L）		LH/（U/L）
对照组		41	31.12±3.16		22.65±3.42		4.23±1.37		5.77±3.01
PCOS组		123	31.30±3.44		26.18±3.20		4.65±1.25		12.40±4.23
t			0.294		6.012^＊＊		1.816		9.287^＊＊
组别	LH/FSH 比值			E₂/（pg/L）		T/ （nmol/L）		PRL/ （nmol/L）		HOMA- IR
对照组	1.35±0.49			46.34±14.50		1.24±0.64		0.72±0.30		2.91±0.50
PCOS组	2.68±0.61			41.90±13.84		3.65±1.26		0.66±0.24		4.25±0.72
t	12.646^＊＊			1.758		11.719^＊＊		1.098		11.051^＊＊

组别		n	年龄/岁		BMI/（kg/m²）		FSH/（U/L）		LH/（U/L）
对照组		41	31.12±3.16		22.65±3.42		4.23±1.37		5.77±3.01
PCOS组		123	31.30±3.44		26.18±3.20		4.65±1.25		12.40±4.23
t			0.294		6.012^＊＊		1.816		9.287^＊＊
组别	LH/FSH 比值			E₂/（pg/L）		T/ （nmol/L）		PRL/ （nmol/L）		HOMA- IR
对照组	1.35±0.49			46.34±14.50		1.24±0.64		0.72±0.30		2.91±0.50
PCOS组	2.68±0.61			41.90±13.84		3.65±1.26		0.66±0.24		4.25±0.72
t	12.646^＊＊			1.758		11.719^＊＊		1.098		11.051^＊＊

组别	n	Angptl2	Angptl4
对照组	41	2.60±0.61	12.81±3.57
PCOS组	123	5.12±0.94	26.11±5.10
t		16.211^＊＊	15.471^＊＊

组别	n	Angptl2	Angptl4
对照组	41	2.60±0.61	12.81±3.57
PCOS组	123	5.12±0.94	26.11±5.10
t		16.211^＊＊	15.471^＊＊

组别	n		PSV/（cm/s）
组别	n		左侧		右侧
对照组	41		6.58±1.03		6.59±1.10
PCOS组	123		9.15±1.25		9.18±1.14
t			11.912^＊＊		12.686^＊＊
组别		PI/%
组别		左侧		右侧
对照组		1.07±0.17		0.94±0.20
PCOS组		0.85±0.16		0.81±0.13
t		7.399^＊＊		4.886^＊＊
组别		RI/%
组别		左侧		右侧
对照组		0.59±0.06		0.58±0.08
PCOS组		0.52±0.08		0.53±0.07
t		4.427^＊＊		3.120^＊＊